LAS VEGAS, Jan. 21, 2020 /PRNewswire/ -- GVB
Biopharma, an industrial hemp company specializing in
cannabinoid-based consumer products, is showcasing its 40,000
square-foot Las Vegas product
manufacturing facility. Consistent with GVB Biopharma's principled
approach to ensuring quality in its consumer products, this
state-of-the-art facility carries all proper licensing and operates
in full compliance with all applicable regulatory requirements.
"Between our central Oregon and
Las Vegas facilities, GVB
Biopharma continues to position itself as an industry-leading,
vertically integrated seed-to-shelf hemp cannabinoid manufacturer,"
says Drew Spiegel, Chief Operating
Officer at GVB Biopharma. This strategy provides quality control in
every stage of operations, from selecting hemp genetics through
finished product manufacturing for wholesale and retail
customers.
GVB Biopharma is currently serving many of the largest
consumer-facing CBD and CBG product companies in the United States, with an expanding private
label and white label business segment to meet market demand. The
product line from GVB Biopharma includes a wide array of
cannabinoids that undergo constant testing to ensure product
quality. There are many available modes of product delivery,
including: gummies, capsules, pressed pills, tinctures, chocolates,
lotions, balms, salves, serums, sprays and vapes.
The company expects its Las
Vegas facility to help drive local economic growth in a
similar manner to its hemp processing facility in central
Oregon where GVB's operations have
created over 100 jobs. With its manufacturing facility in
Las Vegas, GVB aims to replicate
this level of economic development in Las
Vegas.
The company also plans to conduct research studies to provide a
better understanding of cannabigerol and other cutting-edge
cannabinoids. GVB Biopharma will also expand its reach in
pharmaceutical and nutraceutical markets through partnerships and
alliances with like-minded companies committed to process integrity
and product quality.
GVB's fundamental commitment to quality allows the company to
respond proactively to the changing cannabinoid market and to
forthcoming regulations from the FDA. In a largely unregulated
industry, where such quality can be unscrupulously compromised for
profit, GVB Biopharma's approach stands out for its diligence and
forward thinking.
Media Contact: Sebastian Ravitz,
press@gvbbiopharma.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/gvb-biopharma-showcases-40-000sq-ft-manufacturing-facility-in-las-vegas-300988688.html
SOURCE GVB Biopharma